| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/29/2009 | EP1296652B1 Topical pharmaceutical formulations and methods of treatment |
| 04/29/2009 | EP1265927B1 Crystal |
| 04/29/2009 | EP1218509B1 Fibroblast growth factor-like polypeptides |
| 04/29/2009 | CN101420991A Polymer compositions and methods for their use |
| 04/29/2009 | CN101420989A Polymer no donor predrug nanofiber coating for medical devices and therapy |
| 04/29/2009 | CN101420981A Combinations for the treatment of proliferative diseases |
| 04/29/2009 | CN101420980A Compounds and methods for treatment of stroke |
| 04/29/2009 | CN101420979A Method of treatment of myocardial infarction |
| 04/29/2009 | CN101420945A Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis |
| 04/29/2009 | CN101420941A Use of gpr119 receptor agonists for increasing bone mass and for treating osteoporosis, and combination therapy relating thereto |
| 04/29/2009 | CN101417132A Use of medicine combination comprising carvedilol and angiotensin II recipient antagon in preparing medicine for treating kidney disease |
| 04/29/2009 | CN101417131A External medicine combination for treating skin allergic disease |
| 04/29/2009 | CN101417130A Medicine combination for treating II type diabetes and complicating diseases thereof |
| 04/29/2009 | CN101417129A Gabapentin analogues for fibromyalgia and other related disorders |
| 04/29/2009 | CN101416967A Smoking abstention method |
| 04/29/2009 | CN100482688C Human monoclonal antibody against a costimulatory signal transduction molecule AILIM and pharmaceutical use thereof |
| 04/29/2009 | CN100482686C Treatment for diabetes |
| 04/29/2009 | CN100482637C Compounds and compositions for delivering active agents |
| 04/29/2009 | CN100482280C Highly compressible ethylcellulose for tableting |
| 04/29/2009 | CN100482277C Calicheamicin derivative-carrier conjugates |
| 04/29/2009 | CN100482276C Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 04/29/2009 | CN100482221C Use of nefopam for the treatment of nausea or emesis |
| 04/29/2009 | CN100482216C Use of hydroxide-releasing agents as skin permeation enhancers |
| 04/29/2009 | CN100482211C Medicinal targeted local lipolysis |
| 04/28/2009 | US7524949 Prevention or therapy of cardiovascular complications |
| 04/28/2009 | US7524882 PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
| 04/28/2009 | US7524859 Treating hyperproliferative disorders such as gastrointestinal cancer, breast cancer, head cancer, or neck cancer; N-(4-trifluoromethoxyphenyl) 3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide |
| 04/28/2009 | US7524857 Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents |
| 04/28/2009 | US7524850 1-{1-[4-(6-hydroxy-5-isobutyl-3-phenylpyrazin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; serine/threonine protein kinase; antiproliferative |
| 04/28/2009 | US7524828 Immunostimulatory nucleic acid molecules |
| 04/28/2009 | US7524817 Osteogenic protein/bone morphogenetic proteins of eukaryotic origin |
| 04/28/2009 | US7524812 A Omega-conopeptide, and the anitoxidant methionine, and either clonidine or baclofen; ziconotide retains its potency and is physically and chemically compatible with the analgesic; for intrathecal administration |
| 04/28/2009 | US7524679 Methods for culturing human lung mast cells and uses thereof |
| 04/28/2009 | US7524643 Nucleotide sequences coding voltage gated calcium channels (VGCC) for treating neurological and cardiovascular disorders; anticonvulsant |
| 04/28/2009 | US7524514 Three dimensional, malleable cell culture; tissue engineering; pluripotent cells |
| 04/28/2009 | US7524510 Alkyl-glycoside enhanced vaccination |
| 04/28/2009 | US7524500 Method of stimulating stem cells |
| 04/28/2009 | US7524488 Interleukin-18 mutants |
| 04/28/2009 | US7524484 Delivery of diphenhydramine through an inhalation route |
| 04/28/2009 | CA2497171C Water stabilized medicinal aerosol formulation |
| 04/28/2009 | CA2496864C A pharmaceutical composition |
| 04/28/2009 | CA2472954C Aza-arylpiperazines |
| 04/28/2009 | CA2418506C Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases |
| 04/28/2009 | CA2408245C Media milling |
| 04/28/2009 | CA2394672C Biodegradable polymer composition |
| 04/28/2009 | CA2222964C Oxygen activatable formulations for disinfection or sterilization |
| 04/28/2009 | CA2212382C Cochleate delivery vehicles |
| 04/23/2009 | WO2009051824A2 Combination analgesic employing opioid and neutral antagonist |
| 04/23/2009 | WO2009051616A1 Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
| 04/23/2009 | WO2009051238A1 Mouse having human leukemic stem cell and leukemic non-stem cell amplified therein, and method for production thereof |
| 04/23/2009 | WO2009051223A1 Pharmaceutical composition for treatment of cataract |
| 04/23/2009 | WO2009051213A1 Therapeutic agent for leukoderma and method for acceleration of pigmentation |
| 04/23/2009 | WO2009050506A2 Combination 059 |
| 04/23/2009 | WO2009050372A2 Compositions containing lipophosphoramides and use thereof in gene therapy |
| 04/23/2009 | WO2009050159A1 Combination of fluticasone furoate with 4- [ (4-chl0r0phenyl)methyl] -2- ({ (2r)-i- [4-(4-{ [3-(hexahydr0-lh-azepin-l-yl) propyl ] oxy} phenyl) butyl] -2-pyrrolidinyl}methyl) -1 (2h) - phthalaz inone |
| 04/23/2009 | WO2009050136A2 Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome |
| 04/23/2009 | WO2008065485A3 Stable pharmaceutical compositions of a calcium channel blocker and an ace inhibitor |
| 04/23/2009 | WO2006113907A3 Escherichia coli o157:h7 proteins and uses thereof |
| 04/23/2009 | WO2006105538A3 Methods and compositions for treating il-21 related pathologies |
| 04/23/2009 | WO2006055302A3 Method of treating myelodysplastic syndromes |
| 04/23/2009 | WO2005032399A3 Il4 receptor antagonists for horse, dog and cat |
| 04/23/2009 | WO2004028479A9 Nouvelles compositions et methodes de traitement du psoriasis |
| 04/23/2009 | US20090105343 Cancer Therapy And Medicaments Therefor |
| 04/23/2009 | US20090105322 Pharmaceutical composition comprising valsartan |
| 04/23/2009 | US20090105222 Prevention and treatment of functional somatic disorders, including stress-related disorders |
| 04/23/2009 | US20090105197 Use of Sodium Channel Blocking Compounds and Aspirin in Manufacturing Drugs for Producing Analgesia Synergistically in Mammals |
| 04/23/2009 | US20090104694 Isolation and transplantation of retinal stem cells |
| 04/23/2009 | US20090104651 Screening process for antibacterial agents |
| 04/23/2009 | US20090104618 Diagnosing high grade ductal carcinoma (mammary glands) in situ (DCIS) by determining the level of psoriasin gene expression in a sample |
| 04/23/2009 | US20090104285 Methods and Compositions for Use in Treating Cancer |
| 04/23/2009 | US20090104283 Method for reducing the severity of neurological disorders |
| 04/23/2009 | US20090104262 Chlorthalidone combinations |
| 04/23/2009 | US20090104255 Liposome Drug Delivery of Polycyclic, Aromatic, Antioxidant or Anti-Inflammatory Compounds |
| 04/23/2009 | US20090104161 Method for activation treatment of antigen-presenting cell |
| 04/23/2009 | US20090104154 Composition and method for killing of tumours |
| 04/23/2009 | US20090104142 Compositions for treating multiple sclerosis |
| 04/23/2009 | CA2702885A1 Pharmaceutical composition for treatment of cataract |
| 04/23/2009 | CA2702680A1 Combination analgesic employing opioid and neutral antagonist |
| 04/23/2009 | CA2702494A1 Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss |
| 04/23/2009 | CA2702315A1 Combination 059 |
| 04/23/2009 | CA2701037A1 New lipophilic compositions and their uses |
| 04/23/2009 | CA2700729A1 Therapeutic agent for vitiligo and method of accelerating pigmentation |
| 04/22/2009 | EP2050762A2 Novel polypeptides and nucleic acids encoding the same |
| 04/22/2009 | EP2050751A1 Compounds specific to adenosine A1 and A3 receptors and uses thereof |
| 04/22/2009 | EP2050468A1 Agent for treatment of cerebral ischemic diseases |
| 04/22/2009 | EP2050467A1 Therapeutic agent for amyotrophic lateral sclerosis |
| 04/22/2009 | EP2050460A1 PYY and agonists thereof for modification of feeding behaviour |
| 04/22/2009 | EP2050453A1 Pharmaceutical combinations of meloxicam, tramadol and paracetamol |
| 04/22/2009 | EP2050435A1 Cough mixture |
| 04/22/2009 | EP2050344A1 Fish feed |
| 04/22/2009 | EP2049533A2 Quinuclidine derivatives as m3 antagonists |
| 04/22/2009 | EP2049147A2 Human il-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy |
| 04/22/2009 | EP2049139A2 Treatment of ras-expressing tumors |
| 04/22/2009 | EP2049122A1 Methods and compositions for inhibiting angiogenesis |
| 04/22/2009 | EP2049112A2 Treating infections and sequelae thereof with combined dissociated glucocorticoid receptor agonists and anti-infective agents |
| 04/22/2009 | EP2049096A2 Method of treating chronic myelogenous leukemia cells |
| 04/22/2009 | EP2049089A2 Pharmaceutical tablets containing a plurality of active segments |
| 04/22/2009 | EP1641470B1 Vaginal compositions for treating pelvic tissue infections and traumas |
| 04/22/2009 | EP1598079B1 Remedies for allergic contact dermatitis |
| 04/22/2009 | EP1587476A4 Novel compositions and methods in cancer |